# First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.

> **NCT01964287** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 78 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** GEMBRAX
- **DRUG:** FOLFIRINOX

## Key facts

- **NCT ID:** NCT01964287
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-24
- **Primary completion:** 2016-12-22
- **Final completion:** 2020-12-30
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2020-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01964287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01964287, "First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01964287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*